Single subcutaneous doses of ION775 produced rapid, significant, dose-dependent, and durable reductions in apoC-III and TGs, with favorable effects on atherogenic lipoprotein measures and an acceptable safety profile through up to 12 months of follow-up.
S. Tsimikas, E. Morgan, J. Sharma et al.· European Heart Journal· 0 citations
BACKGROUND
Apolipoprotein C-III (apoC-III) regulates triglyceride-rich lipoprotein metabolism. ION775 is a GalNAc-conjugated small interfering RNA designed to silence APOC3 mRNA and enable infrequent dosing.
OBJECTIVE
To evaluate the safety, tolerability, and lipid effects of single-dose ION775 in adults with moderat...
S. Tsimikas, Erin S. Morgan, Jyoti Sharma et al.· Journal of Clinical Lipidolo...· 0 citations
A novel monovalent TfR1-binding VHH-Fc is described for the delivery of oligonucleotide cargo, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) across the BBB in rodents and non-human primates (NHPs), supporting the translational potential of the VHH-antisense RMT platform for the treatme...
Ian J. Huggins, Michele Carrer, Jinro A. Santos et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.